CONCORDE: A phase I platform study of novel agents in combination with conventional radiotherapy in non-small-cell lung cancerGerard Walls, Alastair Greystoke, Jamie B. Oughton et al.|Clinical and Translational Radiation Oncology|2020Cited by 34
Phase 2 study of the IDO/PD-L1-targeted immune-modulatory vaccine, IO102-IO103, plus pembrolizumab as first-line treatment for metastatic non–small cell lung cancer (NSCLC), squamous cell carcinoma of the head and neck (SCCHN), or urothelial bladder cancer (UBC).Jonathan W. Riess, Ezra E.W. Cohen, Shane O’Neill et al.|Journal of Clinical Oncology|2022Cited by 3
P2.01-04 An Update on the CONCORDE study: A Phase Ib Platform Study of Novel Agents in Combination With Conventional Radiotherapy in NSCLCA. Horne, A. Greystoke, Sarah Brown et al.|Journal of Thoracic Oncology|2023Cited by 2